Your browser is no longer supported. Please, upgrade your browser.
Settings
BCRX BioCryst Pharmaceuticals, Inc. daily Stock Chart
BCRX [NASD]
BioCryst Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.15 Insider Own0.20% Shs Outstand112.95M Perf Week-7.14%
Market Cap323.04M Forward P/E- EPS next Y-1.06 Insider Trans-21.60% Shs Float109.30M Perf Month7.12%
Income-125.70M PEG- EPS next Q-0.32 Inst Own92.80% Short Float11.95% Perf Quarter-22.49%
Sales11.50M P/S28.09 EPS this Y-26.00% Inst Trans-0.72% Short Ratio8.71 Perf Half Y-61.25%
Book/sh-0.08 P/B- EPS next Y14.50% ROA-87.60% Target Price7.71 Perf Year-60.98%
Cash/sh0.82 P/C3.50 EPS next 5Y19.90% ROE-371.30% 52W Range2.49 - 9.95 Perf YTD-64.56%
Dividend- P/FCF- EPS past 5Y-12.50% ROI-84.90% 52W High-71.26% Beta1.96
Dividend %- Quick Ratio1.40 Sales past 5Y3.60% Gross Margin86.10% 52W Low14.86% ATR0.20
Employees100 Current Ratio1.40 Sales Q/Q-88.80% Oper. Margin- RSI (14)43.55 Volatility8.00% 7.16%
OptionableYes Debt/Eq- EPS Q/Q-82.60% Profit Margin- Rel Volume3.22 Prev Close2.90
ShortableYes LT Debt/Eq- EarningsAug 06 BMO Payout- Avg Volume1.50M Price2.86
Recom2.30 SMA20-3.85% SMA50-5.94% SMA200-53.70% Volume4,832,868 Change-1.38%
May-24-19Downgrade RBC Capital Mkts Outperform → Sector Perform $16 → $4.50
Nov-16-18Resumed Piper Jaffray Overweight $15
Aug-08-18Resumed JP Morgan Overweight $9
Jul-17-18Upgrade BofA/Merrill Underperform → Neutral
Jun-22-18Initiated Seaport Global Securities Neutral
Jan-02-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Dec-20-17Initiated Barclays Equal Weight $6
Sep-15-17Initiated RBC Capital Mkts Sector Perform $6
Sep-06-17Upgrade JP Morgan Neutral → Overweight
Sep-06-17Upgrade Jefferies Hold → Buy
Feb-16-17Initiated Ladenburg Thalmann Buy $11
Aug-12-16Upgrade Piper Jaffray Neutral → Overweight
Aug-04-16Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-09-16Reiterated FBR Capital Outperform $18 → $6
Feb-09-16Downgrade Needham Buy → Hold
Feb-09-16Downgrade JP Morgan Overweight → Neutral
Feb-09-16Downgrade Jefferies Buy → Hold
Feb-08-16Downgrade Piper Jaffray Overweight → Neutral
Jan-06-16Upgrade Jefferies Hold → Buy
Nov-11-15Downgrade BofA/Merrill Neutral → Underperform
Sep-10-19 07:44AM  Triangle drugmaker looks to rebound with estimated $2 billion global market for new drug American City Business Journals +5.71%
Sep-04-19 07:00AM  BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Sep-03-19 04:15PM  BioCryst to Present at H.C. Wainwright Global Investment Conference GlobeNewswire
Aug-13-19 01:27PM  Edited Transcript of BCRX earnings conference call or presentation 6-Aug-19 12:30pm GMT Thomson Reuters StreetEvents +6.79%
Aug-06-19 05:23PM  Biocryst Pharmaceuticals Inc (BCRX) Q2 2019 Earnings Call Transcript Motley Fool
09:45AM  BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Lags Revenue Estimates Zacks
07:15AM  BioCryst Reports Second Quarter 2019 Financial Results GlobeNewswire
Aug-05-19 07:15AM  BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) GlobeNewswire -7.19%
Jul-30-19 10:38AM  Earnings Preview: BioCryst Pharmaceuticals (BCRX) Q2 Earnings Expected to Decline Zacks
Jul-23-19 07:15AM  BioCryst to Report Second Quarter 2019 Financial Results on August 6 GlobeNewswire
Jul-03-19 07:15AM  BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jul-01-19 07:15AM  BioCryst Appoints Megan Sniecinski Chief Business Officer GlobeNewswire
Jun-27-19 04:15PM  Biocryst Begins Enrollment of Phase 1 Trial of BCX9930, an Oral Factor D Inhibitor for Complement-Mediated Diseases GlobeNewswire
Jun-11-19 08:20PM  Is BioCryst Pharmaceuticals, Inc. (BCRX) A Good Stock To Buy? Insider Monkey -5.54%
Jun-05-19 11:25AM  Edited Transcript of BCRX earnings conference call or presentation 8-May-19 12:30pm GMT Thomson Reuters StreetEvents
Jun-04-19 04:15PM  BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
May-31-19 07:00AM  BioCryst to Present at Upcoming Investor Conferences GlobeNewswire
May-30-19 02:03PM  Here's Why BioCryst Pharmaceuticals Is Soaring Today Motley Fool +15.46%
May-22-19 07:34AM  The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study Benzinga
May-21-19 04:40PM  Why J.C. Penney, Mallinckrodt, and BioCryst Pharmaceuticals Slumped Today Motley Fool -52.91%
02:30PM  In less than six hours today, this Durham company's stock has dropped 50 percent American City Business Journals
01:18PM  Here's Why BioCryst Pharmaceuticals Collapsed Today Motley Fool
10:54AM  BioCryst Trades Sharply Lower Despite Acing Late-Stage Hereditary Angioedema Drug Trial Benzinga
07:00AM  BioCrysts Oral BCX7353 Meets Primary Endpoint in Phase 3 APeX-2 Trial GlobeNewswire
May-14-19 08:46AM  Do Options Traders Know Something About BioCryst Pharmaceuticals (BCRX) Stock We Don't? Zacks
May-10-19 07:00AM  BioCryst to Present at Bank of America Merrill Lynch Health Care Conference GlobeNewswire
May-09-19 04:15PM  BioCryst Completes Phase 1 Clinical Trial of Galidesivir GlobeNewswire
May-08-19 02:23PM  Biocryst Pharmaceuticals Inc (BCRX) Q1 2019 Earnings Call Transcript Motley Fool
09:05AM  BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:59AM  BioCryst: 1Q Earnings Snapshot Associated Press
07:00AM  BioCryst Reports First Quarter 2019 Financial Results GlobeNewswire
May-06-19 07:00AM  BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +5.05%
May-03-19 10:35AM  Heres What Hedge Funds Think About BioCryst Pharmaceuticals, Inc. (BCRX) Insider Monkey
May-01-19 10:33AM  Analysts Estimate BioCryst Pharmaceuticals (BCRX) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-24-19 07:00AM  BioCryst to Report First Quarter 2019 Financial Results on May 8 GlobeNewswire
Apr-04-19 09:36AM  Implied Volatility Surging for BioCryst Pharmaceuticals (BCRX) Stock Options Zacks
Apr-01-19 07:00AM  BioCryst to Present at Upcoming Investor Conferences GlobeNewswire
Mar-25-19 02:10PM  BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): What Can We Expect From This High Growth Stock? Simply Wall St.
Mar-08-19 04:40PM  Edited Transcript of BCRX earnings conference call or presentation 4-Mar-19 1:30pm GMT Thomson Reuters StreetEvents
Mar-06-19 08:20AM  Report: Developing Opportunities within Sarepta Therapeutics, Sally Beauty, Danaher, Ellie Mae, BioCryst Pharmaceuticals, and Akcea Therapeutics Future Expectations, Projections Moving into 2019 GlobeNewswire
Mar-04-19 11:29AM  Biocryst Pharmaceuticals Inc (BCRX) Q4 2018 Earnings Conference Call Transcript Motley Fool
07:02AM  BioCryst Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
07:00AM  BioCryst Advancing BCX9930, an Oral Factor D Inhibitor for Complement-Mediated Diseases, into Phase 1 Development GlobeNewswire
Mar-03-19 09:41AM  The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs Benzinga
Feb-28-19 07:00AM  BioCryst to Present at Barclays Global Healthcare Conference GlobeNewswire
Feb-25-19 10:30AM  Analysts Estimate BioCryst Pharmaceuticals (BCRX) to Report a Decline in Earnings: What to Look Out for Zacks -5.33%
Feb-23-19 12:45PM  BioCryst Reports ZENITH-1 Results With Oral BCX7353 Which Confirm Rapid Onset of Action, Sustained Activity and Robust Dose Response for Treatment of Acute HAE Attacks GlobeNewswire
Feb-18-19 07:00AM  BioCryst to Report Fourth Quarter and Full Year 2018 Financial Results on March 4 GlobeNewswire
Feb-15-19 02:00PM  The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings Benzinga
Feb-14-19 03:30PM  Here Are 5 Biotech Stocks To Love This Valentine's Day: Analyst Investor's Business Daily
Feb-12-19 07:20AM  Detailed Research: Economic Perspectives on Callon Petroleum, Summit Materials, Echo Global Logistics, BioCryst Pharmaceuticals, NEXEO SOLUTIONS, and NL Industries What Drives Growth in Today's Competitive Landscape GlobeNewswire
Feb-06-19 03:10PM  How CEO Stonehouse is building up BioCryst's war chest to finance trials, drug launch American City Business Journals
07:00AM  BioCryst Strengthens Cash Position With Flexible $100 Million Debt Facility GlobeNewswire
Feb-05-19 07:00AM  BioCryst to Present ZENITH-1 Results at American Academy of Allergy, Asthma & Immunology Annual Meeting GlobeNewswire +6.21%
Jan-04-19 07:00AM  BioCryst Appoints Steve Aselage to Board of Directors GlobeNewswire +5.51%
Jan-02-19 07:00AM  BioCryst to Present at 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire +5.33%
07:00AM  BioCryst Initiates Phase 1 Clinical Trial of Galidesivir GlobeNewswire
Dec-27-18 09:23AM  Stocks down in December for pharma firms in the Triangle American City Business Journals
Dec-17-18 06:42PM  Edited Transcript of BCRX earnings conference call or presentation 6-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
Dec-16-18 09:13AM  BioCryst Pharmaceuticals, Inc. (BCRX) Hedge Funds Are Snapping Up Insider Monkey
Nov-27-18 08:55AM  New Research Coverage Highlights Immunomedics, Surmodics, PDF Solutions, Stepan, Express Scripts Holding, and BioCryst Pharmaceuticals Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Nov-20-18 07:00AM  BioCryst Appoints Rare Disease Expert Theresa Heggie to Board of Directors GlobeNewswire +5.97%
Nov-16-18 07:00AM  BioCryst Presents Data Highlighting the Rapid and Sustained Plasma Concentrations of BCX7353 in HAE Patients at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology GlobeNewswire +7.66%
Nov-08-18 07:00AM  BioCryst to Present at Upcoming Investor Conferences GlobeNewswire
Nov-06-18 08:30AM  BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Lags Revenue Estimates Zacks
07:27AM  BioCryst: 3Q Earnings Snapshot Associated Press
07:00AM  BioCryst Reports Third Quarter 2018 Financial Results GlobeNewswire
Nov-05-18 07:00AM  BioCryst to Present Abstracts at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology GlobeNewswire
Oct-30-18 10:33AM  Earnings Preview: BioCryst Pharmaceuticals (BCRX) Q3 Earnings Expected to Decline Zacks
Oct-23-18 04:15PM  BioCryst to Report Third Quarter 2018 Financial Results on November 6 GlobeNewswire
Oct-16-18 07:50AM  Analysis: Positioning to Benefit within Ardelyx, AXT, TG Therapeutics, MarineMax, Oclaro, and BioCryst Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Oct-12-18 09:17AM  Grifols (GRFS) Surges: Stock Moves 5.4% Higher Zacks +5.73%
Sep-25-18 04:15PM  BioCryst Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-17-18 07:00AM  BioCryst Receives Additional $3.5 Million to Fund Clinical Trials of Galidesivir in Yellow Fever GlobeNewswire
Sep-10-18 12:36PM  Here's Why BioCryst Pharmaceuticals Rose 21.3% in August Motley Fool
Sep-06-18 01:45PM  RTP pharma scores $35M contract to supply CDC American City Business Journals
07:37AM  BioCryst stock surges 6% premarket after winning $35 million CDC contract for flu therapy MarketWatch
07:00AM  CDC Awards BioCryst $35 Million RAPIVAB® Contract for Strategic National Stockpile GlobeNewswire
Sep-05-18 08:28AM  The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results Benzinga +5.27%
Sep-04-18 02:38PM  Inside The List: Highest-Paid Public Company CEOs American City Business Journals +6.01%
12:15PM  CORRECTION -- BioCryst Reports Positive Results Across Multiple Endpoints in ZENITH-1 Trial of Oral BCX7353 as Acute Therapy for Hereditary Angioedema (HAE) Attacks GlobeNewswire
07:00AM  BioCryst Reports Positive Results Across Multiple Endpoints in ZENITH-1 Trial of Oral BCX7353 as Acute Therapy for Hereditary Angioedema (HAE) Attacks GlobeNewswire
Aug-29-18 07:00AM  BioCryst Pharmaceuticals to Present at the Baird Global Healthcare Conference GlobeNewswire
Aug-20-18 01:50PM  Edited Transcript of BCRX earnings conference call or presentation 7-Aug-18 3:00pm GMT Thomson Reuters StreetEvents
Aug-15-18 08:00AM  New Research Coverage Highlights Cincinnati Bell, BioCryst Pharmaceuticals, Shutterstock, Kopin, Lands' End, and Pieris Pharmaceuticals Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Aug-07-18 03:38PM  BioCryst banks gross proceeds of $57.5M from offering American City Business Journals
07:30AM  BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates Zacks
06:05AM  BioCryst: 2Q Earnings Snapshot Associated Press
06:00AM  BioCryst Reports Second Quarter 2018 Financial Results GlobeNewswire
Aug-06-18 04:01PM  BioCryst Pharmaceuticals Announces Full Exercise of Underwriters Option to Purchase Additional Shares and Completion of Public Offering of Common Stock GlobeNewswire
02:18PM  BioCryst gets FDA nod on key drug American City Business Journals
06:00AM  U.S. FDA Grants Fast Track Designation for BioCrysts BCX7353 GlobeNewswire
Aug-02-18 04:13PM  After Idera deal called off, BioCryst looks to raise $50M American City Business Journals +9.96%
02:40PM  Why BioCryst Pharmaceuticals Stock Is Bolting Higher Today Motley Fool
08:54AM  The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter Benzinga
Aug-01-18 09:59PM  BioCryst Pharmaceuticals Prices Public Offering of Common Stock GlobeNewswire -6.44%
04:01PM  BioCryst Pharmaceuticals Commences Public Offering of Common Stock GlobeNewswire
Jul-27-18 09:00AM  BioCryst to Announce Second Quarter 2018 Financial Results on August 7 GlobeNewswire
Jul-25-18 06:00PM  BioCryst Announces Publication of APeX-1 Clinical Trial Results for BCX7353 in The New England Journal of Medicine GlobeNewswire
Jul-24-18 07:30AM  Stock Performance Review on AVEO Pharma and Three Other Biotech Stocks ACCESSWIRE
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in preclinical trials to treat fibrodysplasia ossificans progressive; and Galidesivir, an RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ASELAGE STEVEDirectorMay 22Buy3.573,00010,7105,000May 24 04:20 PM
STAAB THOMAS R IISenior Vice President and CFOMay 17Sale7.452,50018,625125,176May 20 04:21 PM
STAAB THOMAS R IISenior Vice President and CFOMay 16Option Exercise1.424,7506,745134,926May 20 04:21 PM
STAAB THOMAS R IISenior Vice President and CFOMay 16Sale7.727,25055,970127,676May 20 04:21 PM
STAAB THOMAS R IISenior Vice President and CFOMay 15Option Exercise1.424,7506,745137,426May 16 04:29 PM
STAAB THOMAS R IISenior Vice President and CFOMay 15Sale7.927,25057,420130,176May 16 04:29 PM
STAAB THOMAS R IISenior Vice President and CFOMay 14Option Exercise1.424,5006,390137,176May 16 04:29 PM
STAAB THOMAS R IISenior Vice President and CFOMay 14Sale7.624,50034,290132,676May 16 04:29 PM
STAAB THOMAS R IISenior Vice President and CFOMay 13Option Exercise5.519,75053,723142,426May 13 04:57 PM
STAAB THOMAS R IISenior Vice President and CFOMay 13Sale7.769,75075,660132,676May 13 04:57 PM
STAAB THOMAS R IISenior Vice President and CFOMay 09Option Exercise5.519,75053,723142,426May 13 04:57 PM
STAAB THOMAS R IISenior Vice President and CFOMay 09Sale7.639,75074,393132,676May 13 04:57 PM
STAAB THOMAS R IISenior Vice President and CFOMay 06Option Exercise5.519,00049,590141,676May 06 04:51 PM
STAAB THOMAS R IISenior Vice President and CFOMay 06Sale7.759,00069,750132,676May 06 04:51 PM
STAAB THOMAS R IISenior Vice President and CFOMay 02Option Exercise5.517,75042,703140,426May 06 04:51 PM
STAAB THOMAS R IISenior Vice President and CFOMay 02Sale7.307,75056,575132,676May 06 04:51 PM
STAAB THOMAS R IISenior Vice President and CFOApr 04Option Exercise5.517,50041,325140,176Apr 08 02:30 PM
STAAB THOMAS R IISenior Vice President and CFOApr 04Sale8.817,50066,075132,676Apr 08 02:30 PM
ASELAGE STEVEDirectorMar 12Buy8.302,00016,6002,000Mar 14 04:18 PM
Powell LynneSenior VP - CCOJan 28Option Exercise3.226,00019,3204,000Jan 29 04:21 PM
STAAB THOMAS R IISenior Vice President and CFOJan 28Option Exercise5.455,00027,250133,426Jan 30 04:10 PM
STAAB THOMAS R IISenior Vice President and CFOJan 28Sale9.855,00049,250128,426Jan 30 04:10 PM
Powell LynneSenior VP - CCOJan 28Sale9.896,00059,3400Jan 29 04:21 PM
Powell LynneSenior VP - CCOJan 25Option Exercise3.226,00019,3206,000Jan 29 04:21 PM
Powell LynneSenior VP - CCOJan 25Sale9.606,00057,6000Jan 29 04:21 PM
Powell LynneSenior VP - CCOJan 18Option Exercise3.222,0006,4402,000Jan 23 04:12 PM
Powell LynneSenior VP - CCOJan 18Sale9.402,00018,8000Jan 23 04:12 PM
Powell LynneSenior VP - CCOJan 16Option Exercise3.223,0469,8083,046Jan 18 04:03 PM
Powell LynneSenior VP - CCOJan 16Sale9.273,04628,2360Jan 18 04:03 PM
Powell LynneSenior VP - CCOJan 14Option Exercise3.229543,072954Jan 16 04:24 PM
Powell LynneSenior VP - CCOJan 14Sale9.209548,7770Jan 16 04:24 PM
Sheridan William PSenior VP - CMODec 18Sale7.5820,488155,2992,725Dec 20 04:37 PM
Powell LynneSenior VP - CCODec 10Option Exercise3.224,00012,8802,000Dec 12 04:13 PM
Powell LynneSenior VP - CCODec 10Sale9.064,00036,2400Dec 12 04:13 PM
STAAB THOMAS R IISenior Vice President and CFODec 04Sale9.453,92237,063133,461Dec 06 04:30 PM
Stonehouse Jon PPresident & CEODec 03Option Exercise1.2080,00096,000807,674Dec 06 04:34 PM
Stonehouse Jon PPresident & CEODec 03Sale9.1280,000729,600727,674Dec 06 04:34 PM
Barnes Alane PSenior VP, Chief Legal OfficerNov 30Option Exercise1.4225,00035,500122,243Dec 04 04:11 PM
Barnes Alane PSenior VP, Chief Legal OfficerNov 30Sale9.0744,290401,71077,953Dec 04 04:11 PM
Erck Stanley CDirectorNov 28Option Exercise1.498,33312,41648,333Nov 30 04:02 PM
STAAB THOMAS R IISenior Vice President and CFONov 23Option Exercise3.783,50013,230140,883Nov 26 04:19 PM
STAAB THOMAS R IISenior Vice President and CFONov 23Sale9.663,50033,810137,383Nov 26 04:19 PM
STAAB THOMAS R IISenior Vice President and CFONov 21Option Exercise4.4812,00053,710144,383Nov 26 04:19 PM
Powell LynneSenior VP - CCONov 21Option Exercise3.2212,00038,64014,455Nov 26 04:22 PM
Powell LynneSenior VP - CCONov 21Sale9.0514,455130,8400Nov 26 04:22 PM
STAAB THOMAS R IISenior Vice President and CFONov 21Sale9.2212,000110,610137,383Nov 26 04:19 PM
STAAB THOMAS R IISenior Vice President and CFONov 20Option Exercise3.4511,12338,405143,883Nov 21 04:48 PM
Powell LynneSenior VP - CCONov 20Option Exercise3.229,12729,38917,732Nov 21 04:51 PM
Powell LynneSenior VP - CCONov 20Sale8.5615,277130,7142,455Nov 21 04:51 PM
STAAB THOMAS R IISenior Vice President and CFONov 20Sale8.6811,12396,494137,383Nov 21 04:48 PM
Powell LynneSenior VP - CCONov 19Option Exercise3.221936218,798Nov 21 04:51 PM
STAAB THOMAS R IISenior Vice President and CFONov 19Option Exercise3.7875284137,458Nov 21 04:48 PM
Powell LynneSenior VP - CCONov 19Sale8.301931,6028,605Nov 21 04:51 PM
STAAB THOMAS R IISenior Vice President and CFONov 19Sale8.3075623137,383Nov 21 04:48 PM
Powell LynneSenior VP - CCONov 08Option Exercise3.225,28017,00213,885Nov 09 04:11 PM
STAAB THOMAS R IISenior Vice President and CFONov 08Option Exercise3.3213,41544,485148,496Nov 09 04:14 PM
Powell LynneSenior VP - CCONov 08Sale8.155,28043,0328,605Nov 09 04:11 PM
STAAB THOMAS R IISenior Vice President and CFONov 08Sale8.1313,415109,011137,383Nov 09 04:14 PM
STAAB THOMAS R IISenior Vice President and CFONov 07Option Exercise3.226722,164138,055Nov 09 04:14 PM
Powell LynneSenior VP - CCONov 07Option Exercise3.223009668,905Nov 09 04:11 PM
STAAB THOMAS R IISenior Vice President and CFONov 07Sale8.006725,376137,383Nov 09 04:14 PM
Powell LynneSenior VP - CCONov 07Sale8.003002,4008,605Nov 09 04:11 PM
STAAB THOMAS R IISenior Vice President and CFONov 05Option Exercise3.22215692137,598Nov 07 04:03 PM
Powell LynneSenior VP - CCONov 05Option Exercise3.221003228,705Nov 07 04:05 PM
Powell LynneSenior VP - CCONov 05Sale8.001008008,605Nov 07 04:05 PM
STAAB THOMAS R IISenior Vice President and CFONov 05Sale8.002151,720137,383Nov 07 04:03 PM
Powell LynneSenior VP - CCONov 02Option Exercise3.221,0003,2209,605Nov 06 04:07 PM
STAAB THOMAS R IISenior Vice President and CFONov 02Option Exercise3.4010,85636,916144,739Nov 06 04:04 PM
Powell LynneSenior VP - CCONov 02Sale8.001,0008,0008,605Nov 06 04:07 PM
STAAB THOMAS R IISenior Vice President and CFONov 02Sale7.8410,85685,090137,383Nov 06 04:04 PM
Powell LynneSenior VP - CCONov 01Sale7.511,54411,5958,605Nov 05 01:17 PM
STAAB THOMAS R IISenior Vice President and CFOOct 19Option Exercise3.783,15011,907140,533Oct 23 01:34 PM
STAAB THOMAS R IISenior Vice President and CFOOct 19Sale7.453,15023,468137,383Oct 23 01:34 PM
Powell LynneSenior VP - CCOOct 19Sale7.5010075010,149Oct 23 01:31 PM
STAAB THOMAS R IISenior Vice President and CFOOct 03Option Exercise3.271,0723,508138,355Oct 04 01:09 PM
STAAB THOMAS R IISenior Vice President and CFOOct 03Sale7.281,0727,802137,383Oct 04 01:09 PM
STAAB THOMAS R IISenior Vice President and CFOOct 02Option Exercise3.438,77830,085142,911Oct 04 01:09 PM
STAAB THOMAS R IISenior Vice President and CFOOct 02Sale7.248,77863,556137,383Oct 04 01:09 PM